Skip to main content

James E Galvin

NIH Rank #98
  • Top 1% Funded
  • Program Leader
  • R01 Holder
  • Multi-Institutional
  • Early Career
  • Mentor

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 2085729Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Neurology

NIH Funding · FY2025

Linked Award Amount
$20.4M
Full award amounts, FY2025
Award Records
6
Records listing this PI
Award-Linked Rank
#98
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for James E Galvin. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing James E Galvin as a PI. Multi-PI records show the full award amount for context.

  • 5R01AG080536-03R01
    A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
    $6.1M
    award amount
  • 1R01AG092949-01R01
    FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
    $5.3M
    award amount
  • 4RF1AG075904-02RF1
    Alzheimer's Disease and Related Dementias (ADRD) prevalence in American Samoa
    $4.1M
    award amount
  • 5R01AG071514-05R01
    Multicultural Community Dementia Screening
    $2.5M
    award amount
  • 5U01AG084528-02U01
    IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
    $1.8M
    award amount
  • 5T32AG081170-02T32
    Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)
    $558.7K
    award amount

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Institute for Molecular Medicine
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    $10M Cumulative Funding
  7. 2024
    Entered Top 50% Nationally
    Ranked #170
  8. 2024
    Entered Top 25% Nationally
    Ranked #170
  9. 2024
    Entered Top 10% Nationally
    Ranked #170
  10. 2024
    Entered Top 5% Nationally
    Ranked #170
  11. 2024
    Entered Top 1% Nationally
    Ranked #170
  12. 2025
    $25M Cumulative Funding
  13. 2025
    Multi-Institutional Research
    Awards at 4 institutions
  14. 2025
    R01 Grant Holder
  15. 2025
    Program/Center Grant Leader